FINWIRES · TerminalLIVE
FINWIRES

UBS Downgrades Legend Biotech to Neutral From Buy, Adjusts Price Target to $28 From $49

By

Legend Biotech (LEGN) has an average rating of overweight and mean price target of $53.73, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

Related Articles

UBS Downgrades Legend Biotech to Neutral From Buy, Adjusts Price Target to $28 From $49 | FINWIRES